March 13, 2019―Bio Preventive Medicine today announce its participation in the upcoming 2nd Annual Chronic Kidney Disease Drug Development (CKD3) Summit, which will gather stakeholders and decision-makers from the USFDA, academia, and influential international pharma across the globe. Dr. Tzu-Ling (Karen) Tseng, CEO of BPM, is arranged to deliver a talk, Innovative Renal Diagnostic Solution for Management of CKD, on May 6th from 11:30-12:00. As a solution provider, BPM can assist our pharma partners in drug development, not only for evaluating renal efficacy, but also renal safety. We believe this is an excellent exposure for BPM to become a global player in CKD drug development area.